Listed

Nurix Therapeutics, Inc.: Form 10-Q for the period ended Aug 31, 2020

Filed with the SEC on Oct 14, 2020 and accepted by EDGAR at Oct 14, 2020, 16:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-08-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-06-01 to 2020-08-31$18.9mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-12-01 to 2020-08-31$46.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-06-01 to 2020-08-31−$19.2mus-gaap:OperatingIncomeLoss
Operating income9 months2019-12-01 to 2020-08-31−$45.0mus-gaap:OperatingIncomeLoss
Income tax9 months2019-12-01 to 2020-08-31−$20.6mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-06-01 to 2020-08-31−$18.5mus-gaap:NetIncomeLoss
Net income9 months2019-12-01 to 2020-08-31−$23.3mus-gaap:NetIncomeLoss
Operating cash flow9 months2019-12-01 to 2020-08-31$20.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-12-01 to 2020-08-31$3.6mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-08-31$265.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-08-31$364.1mus-gaap:AssetsCurrent
Total assetsAt period end2020-08-31$411.9mus-gaap:Assets
Current liabilitiesAt period end2020-08-31$41.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-08-31$104.3mus-gaap:Liabilities
Shareholders' equityAt period end2020-08-31$307.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-20-046400. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.